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Abstract
Background: The calcium-binding protein calretinin (gene name: CALB2) is currently considered as the most
sensitive and specific marker for the diagnosis of malignant mesothelioma (MM). MM is a very aggressive tumor
strongly linked to asbestos exposure and with no existing cure so far. The mechanisms of calretinin regulation, as
well as its distinct function in MM are still poorly understood.
Methods: We searched for transcription factors binding to the CALB2 promoter and modulating calretinin
expression. For this, DNA-binding assays followed by peptide shotgun-mass spectroscopy analyses were used.
CALB2 promoter activity was assessed by dual-luciferase reporter assays. Furthermore, we analyzed the effects of
CALB2 promoter-binding proteins by lentiviral-mediated overexpression or down-regulation of identified proteins in
MM cells. The modulation of expression of such proteins by butyrate was determined by subsequent Western blot
analysis. Immunohistochemical analysis of embryonic mouse lung tissue served to verify the simultaneous co-expression
of calretinin and proteins interacting with the CALB2 promoter during early development. Finally, direct interactions of
calretinin with target proteins were evidenced by co-immunoprecipitation experiments.
Results: Septin 7 was identified as a butyrate-dependent transcription factor binding to a CALB2 promoter region
containing butyrate-responsive elements (BRE) resulting in decreased calretinin expression. Accordingly, septin 7
overexpression decreased calretinin expression levels in MM cells. The regulation was found to operate bi-directionally,
i.e. calretinin overexpression also decreased septin 7 levels. During murine embryonic development calretinin and
septin 7 were found to be co-expressed in embryonic mesenchyme and undifferentiated mesothelial cells. In MM cells,
calretinin and septin 7 colocalized during cytokinesis in distinct regions of the cleavage furrow and in the midbody
region of mitotic cells. Co-immunoprecipitation experiments revealed this co-localization to be the result of a direct
interaction between calretinin and septin 7.
Conclusions: Our results demonstrate septin 7 not only serving as a “cytoskeletal” protein, but also as a transcription
factor repressing calretinin expression. The negative regulation of calretinin by septin 7 and vice versa sheds new light
on mechanisms possibly implicated in MM formation and identifies these proteins as transcriptional regulators and
putative targets for MM therapy.
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Background
The Ca2+-binding protein calretinin (CR) serves as an
undisputed marker for the diagnosis of human malignant
mesothelioma (MM), in particular of the epithelioid type
and the epithelioid parts of the mixed type [1, 2]; weak CR
expression is also found in sarcomatoid MM, possibly
indicating a less important and/or different role of CR in
this MM cell type [3]. CR is also expressed in human
reactive mesothelial cells [4, 5], considered as the first step
in the transition from healthy flat mesothelial cells
covering the pleural cavities to one of the most aggressive
and currently therapy-resistant tumor type. Down-
regulation of CR by CALB2 shRNA in human MM cell
lines profoundly decreases cell growth and viability in
vitro: lentivirus-mediated delivery of shCALB2 causes
MM cells, in particular the ones with an epithelioid
morphology, to enter apoptosis within 72 h post-infection
[3]. Under these conditions, the intrinsic caspase 9-
dependent pathway is activated. Although the immortal-
ized mesothelial cells LP9/TERT1 show strong CR
expression (3), shRNA-mediated CR down-regulation dif-
ferently affects these non-transformed cells: it inhibits cell
proliferation as the result of a G1 block. Neither is the via-
bility impaired nor any type of cell death pathway activated.
CR is a fast Ca2+ buffer protein [6, 7] modifying the
shape of intracellular Ca2+ transients [8]; overexpression
of CR reduces the mitochondrial Ca2+ uptake in primary
mesothelial cells [9]. Very little is known about the
regulation of CR expression in the various tissues, even
in the subpopulation of neurons, where CR is expressed
under physiological conditions. It is assumed that CR
expression is regulated in a rather similar way in humans
and in mice, mostly based on the strong conservation of
the proximal promoter regions of the human CALB2 and
mouse Calb2 genes [10]. An AP2-like element in proxim-
ity of the TATA box confers neuron-specific expression of
a luciferase reporter gene (luc+) in cultured neurons [11]
(for additional details, see Fig. 1 in [12]), necessitating the
binding of a nuclear protein present in cerebellar granule
cells. Of note, this “AP2-like” element in the promoter re-
gion has no effect on the transcriptional activity in either
MM cells or CR-expressing human colon cancer cells.
Down-regulation of β-catenin by its negative regulator
Axin2 significantly reduces CR expression in cultured rat
thalamic neurons indicating that β-catenin is a positive
regulator of the Calb2 gene [13]. A more detailed CALB2
promoter analysis revealed the sequence embracing the −
161/+ 80 bp region to sustain transcriptional activity in
MM cells. Cis-regulatory elements within this promoter
region including binding sites for NRF-1 and E2F2 are
important for CR expression; e.g. siRNA-mediated down-
regulation of NRF-1 causes a decrease in CR expression
levels indicating that NRF-1 acts as a positive regulator of
CR expression (14). Moreover, the strong correlation
between CALB2 mRNA and CR protein expression levels
in MM cells is indicative of a control at the transcriptional
level [14]. In colon cancer cells, two butyrate-responsive
elements (BRE) embracing the TATA box of the CALB2
gene function as butyrate-sensitive repressors of CR ex-
pression, while the same sequence has no effect in cells of
mesothelial origin, e.g. Met-5A cells [15]. Butyrate (Bt) is
the product resulting from intestinal fermentation of diet-
ary fibers by bacteria and Bt concentrations in the range
of 5–30 mM are present in the chyme/feces of the gut
[16]. Bt acts as a modulator of histone acetylation that re-
sults in the inhibition of the cell cycle (G1 arrest) and leads
to enterocyte (and derived cancer cells) differentiation
[17]. Bt exposure of CR-expressing WiDr colon cancer
cells results in CR down-regulation [18]. Moreover, gut
microbiota might have an influence on respiratory infec-
tions [19] also via short chain fatty acids (SFCA) including
Bt. Bt is not only produced by the gut microbiota, but also
by anaerobic bacteria in the hypoxic environment of cystic
fibrosis (CF) airways. Bt concentrations were found to be
elevated in the sputum samples of CF patients reaching
values of approximately 2 mM [20] and it is conceivable
that in the diseased lung of MM patients, Bt may also be
increased in the pleural cavity.
In the present study, short-term exposure of MM-
derived cell lines to low millimolar Bt concentrations
revealed a significant increase in CR expression levels.
Thus, we set out to investigate in more detail the
promoter region of the CALB2 gene that acts as a Bt-
responsive enhancer in MM cells. To address the ques-
tion on mechanisms implicated in this regulation, we
searched for proteins binding to this particular promoter
region that might be functionally implicated in CR regu-
lation in MM cells.
Methods
Cell culture
The human mesothelioma cell lines MSTO-211H, H28,
H226, the immortalized mesothelial cell line Met-5A
and the colorectal adenocarcinoma HT-29 were obtained
from the American Type Cell Collection (ATCC, Rock-
ville, MD). The human mesothelioma cell lines ZL5,
ZL34, ZL55, SPC111 and SPC212 were obtained from
the University Hospital of Zurich (Switzerland) de-
scribed by Schmitter et al. [21]. Cells were maintained in
RPMI1640 (Gibco, Basel, Switzerland) supplemented
with 10% fetal bovine serum (FBS, Gibco) and 100 U/ml
penicillin and 100 μg/ml of streptomycin (1% PS, Gibco).
LP9/TERT-1 cells were obtained from the laboratory of
Dr. James Rheinwald (Dana Farber Cancer Research
Institute, Boston, MA) and were maintained in a
medium consisting of 1:1 M199 and MCDB10 medium
supplemented with 15% newborn calf serum, 5 ng/mL
epidermal growth factor, 0.4 μg/mL hydrocortisone,
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2 mM glutamine, 100 U/ml penicillin and 100 μg/ml
streptomycin (1% PS) (Gibco, Switzerland).
Generation of reporter plasmids including deletion variants
of the human CALB2 promoter containing BRE7–13
Genomic DNA was isolated from MSTO-211H and
ZL55 MM cells using standard methods and purified
DNA (0.5 μg) was used as template to amplify a 1.3 kb
stretch of the human CALB2 promoter embracing the
putative Bt-responsive elements (BRE) 7–13; the se-
quence and details of primers are shown in Fig. 2 and
Table 1. The amplicon of 1292 bp containing a SacI and
a BglII site at the 5′- and 3′-end, respectively, was
cloned into the plasmid pGL3-Promotor (pGL3-P; Pro-
mega; # U47298; Wallisellen, Switzerland) linearized
with the same restriction enzymes. pGL3-P contains a
multiple cloning site, followed by a minimal SV40 pro-
moter; the luciferase cassette (luc) in the plasmid is
followed by a SV40 late poly (A) signal. This plasmid
was then used to generate shorter PCR fragments
containing a various number of BREs (see Fig. 2 and
Table 1), the fragments were cloned into pGEM-TEasy,
sequenced (Microsynth AG, Balgach, Switzerland) and
excised by SacI and BglII. The fragments were then
inserted into pGL3-P for transfection experiments; DNA
(300–500 μg) was isolated using the Wizard Plus Midi-
or Maxiprep kit (Promega, Dübendorf, Switzerland).
Luciferase assay
In order to investigate CALB2 promoter activity the dual
luciferase assay was used. The constructs were co-
transfected with Renilla-Luciferase in 12-well plates
(50,000 cells/well) with Mirus lipofection reagent (Mirus,
WI, USA). After 48 h (± Bt treatment; 1 mM) the cells
were lysed and promoter activity was measured with the
dual-luciferase reporter assay (Promega, Dübendorf,
Switzerland) on a Turner Designs TD-20/20 Lumin-
ometer (Sunnyvale, CA, USA) according to the manufac-
turer’s protocol. The details on the normalization of
signals and the way to calculate fold changes compared
to untreated controls have been described before [15].
DNA binding assay
The fragment containing BRE9–13 (706 bp) serving as
capture DNA was synthesized by PCR using 5′-biotinyl-
ated primers. The μMACS™ FactorFinder kit (Mylteni
Biotech, Bergisch Gladbach, Germany) was used to iso-
late proteins interacting with this stretch of the CALB2
promoter. The cleared cell lysate (15,000 x g, 5 min)
from 107 MSTO-211H cells (100 μl) was incubated with
1.5 μg of biotinylated BRE9–13 DNA. Putative transcription
factor complexes were isolated under non-denaturing (na-
tive) conditions according to the manufacturer’s protocol.
Western blot analysis and silver staining
Cell pellets were collected and washed 3 times with
CMF-PBS. Cytosolic fractions were isolated as described
before [22] and the concentration of proteins was deter-
mined using the Bradford method (Bio-Rad, Hercules,
CA). Samples were loaded and separated by SDS-PAGE
(10% PAA) and subsequently transferred onto nitrocellu-
lose membranes (Bio-Rad) by a semidry system (Witec,
Litau, Switzerland). Equal protein loading was controlled
by transient Ponceau S staining (Sigma) of the mem-
branes. The primary antibodies against calretinin
(CR7699/4; Swant, Marly, Switzerland) and septin 7
(rabbit polyclonal anti-septin 7; Bethyl Laboratories Inc.,
Montgomery, TX, USA or Millipore Corp. #ABT354, Te-
mecula, CA, USA) were used at a dilution of 1:5000
overnight at 4 °C; anti-GAPDH was from Sigma (ref.
G9545) and used at a working dilution of 1:10,000.
Rabbit secondary antibody directly linked to horseradish
peroxidase (Sigma-Aldrich) was diluted 1:10,000 and
membranes were incubated for 2 h at room temperature.
The detection was performed with the chemilumines-
cent reagent Luminata Classico or Forte (EMD Millipore
Corporation, Billerica, MA, USA) and data were col-
lected on an imaging system from Cell Biosciences
(Santa Clara, CA, USA).
For normalization and quantification of Western blots,
densitometric analysis of the Ponceau S-stained mem-
branes was performed using the GeneTools software
(Syngene, Cambridge, UK). The integral of the signals of
all transferred proteins was previously shown to repre-
sent a more reliable way of normalization, since this re-
duces the bias towards a specific protein (e.g. GAPDH,
α-actin) often used for normalization. Levels of reference
(housekeeping) proteins were shown to vary between tis-
sues or different cell lines and might also be affected by
the experimental manipulations [23, 24]. GeneTools soft-
ware was also used for the quantification of the specific
Western blots signals for CR, septin 7 and GAPDH. In
the results section, most often only selected representa-
tive regions of the Ponceau S-stained membranes
marked as loading control (L.C.) are shown, in particular
when Western blot signals were analyzed qualitatively.
Septin 7 cDNA cloning into pLVTHM backbone
A lentiviral system was used to overexpress septin 7.
Briefly, the GFP cassette in pLVTHM (Addgene plasmid
#12247) was replaced with the human septin 7 (SEPT7)
cDNA using the SpeI and PmeI restriction sites. SEPT7
cDNA was obtained from ZL55 cell total RNA. RNA
was extracted using the Qiagen RNAeasy kit following
the manufacturer’s instructions; cDNA was synthetized
from 500 ng of total RNA using the QuantiTect Reverse
Transcription kit (Qiagen). Septin 7 was amplified with
the following primers: FW_hSEPT7 5′-AGT CGT TTA
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AAC ATG TCG GTC AGT GCG AGA TCC-3′ and
RV_hSEPT7 5′-AGT CAC TAG TTT AAA AGA TCT
TCC CTT TCT T-3′ containing the SpeI and PmeI
restriction sites, respectively and the amplicon was
inserted into the vector pLVTHM. The correct sequence
of the plasmid was verified by colony PCR and subse-
quent sequencing of the insert and the novel plasmid
was called pLV-hSEPT7.
Lentiviral constructs
Lentivirus particles were produced as described before
[3, 25]. Briefly, HEK293T cells were co-transfected by
the CaPO4-method with 3 μg of the envelope plasmid
pMD2.G-VSVG (Addgene plasmid #12259), 8 μg of the
packaging plasmid psPAX2 (Addgene plasmid # 12260)
and either 10 μg of the transfer plasmid pLV-CALB2 as
described in [25] or the plasmid containing the shRNA
for CALB2 as reported before [3]. Five validated clones
of pLKO.1-shRNA SEPT7 plasmids were obtained from
Sigma-Aldrich labeled 1–4 and 63 (according to the last
digit of The RNAi Consortium (TRC) number). pLV-
hSEPT7 was used to overexpress septin 7.
Immunohistochemistry on sections of mouse embryos
from E10.5
Mouse embryos were collected at embryonic day 10.5
(E10.5) from C57Bl/6J mice and fixed by immersion in
4% PFA for 72 h, dehydrated and embedded in paraffin.
Sections (3 μm) were de-paraffinized and treated with
Tris/EDTA (1 mM/0.1 mM, pH 9) for the antigen re-
trieval by heating the sections in a boiling water bath for
20 min. Hydrogen peroxide (0.3%; 20 min incubation)
served to quench endogenous peroxidases and the tissue
was permeabilized with 0.1% PBS Tween20 (5 min incu-
bation) followed by blocking with PBS containing 2%
BSA and 1% horse serum (20 min incubation). Sections
were incubated with primary antibodies (anti-CR 7699/
4, Swant, Switzerland, anti-septin 7, Bethyl Laboratories,
USA) 1:500 overnight at 4 °C. Sections were incubated with
secondary antibodies (1:200 dilution) at room temperature
for 2 h. After DAB (Sigma-Aldrich) staining, sections were
subjected to (weak) hematoxylin counterstaining. Slides
were scanned using a whole-slide imaging system from Ha-
mamatsu (Nanozoomer, 2.0-HT).
Immunofluorescence
Cells were seeded on 12-mm glass coverslips and fixed
for 15 min with 4% paraformaldehyde. Non-specific
binding sites were blocked by incubation with TBS con-
taining donkey serum (10%) for 1 h and coverslips were
then incubated overnight at 4 °C with the following anti-
bodies diluted in TBS 1X: goat polyclonal anti-CR (1:
500; cat# CG1, Swant, Marly, Switzerland) and rabbit
polyclonal anti-septin 7 (1:500; Bethyl Laboratories,
USA). After washing, coverslips were incubated with
secondary antibodies for 3 h at room temperature with
the following secondary antibodies: Alexa Fluor 488-
conjugated donkey anti-rabbit IgG (1:100, Jackson
Immunoresearch Laboratories, West Grove, PA, USA)
and Cy5-conjugated donkey anti-goat IgG (1:100; Jack-
son). Nuclear DNA was stained using DAPI (5 μg/ml;
Molecular Probes, Eugene, OR) and coverslips were
mounted with Hydromount solution (National Diagnos-
tics, Atlanta, GA). Images were acquired using a Leica
fluorescent microscope DM6000B (Wetzlar, Germany)
equipped with a Hamamatsu camera C4742–95 (Bridge-
water, NJ). For the cells treated with Bt, cells were
seeded onto 12-mm glass coverslips pre-coated with
Matrigel (Corning, NY, USA) and treated with 1 mM Bt
for 48 h.
Co-immunoprecipitation (co-IP)
MM cells at a confluence of 70–90% were washed with
ice-cold PBS and lysed with 1 ml ice-cold Triton X-100
lysis buffer (150 mM NaCl, 1% Triton X-100, 50 mM
Tris-HCl, pH 8.0) supplemented with protease and
phosphatase inhibitors. Cell lysates were incubated on
ice for 30 min and then centrifuged (10,000×g, 10 min at
4 °C). To pull down CR, 2–4 μg of a rabbit polyclonal
anti-CR antiserum (CR7699/4; Swant) was added to the
cleared lysate and incubated for 10 min at 4 °C. μMACS
protein A MicroBeads suspension (100 μl; Miltenyi Bio-
tec, Auburn, CA, USA) was added to the lysate and in-
cubated at 4 °C for 30 min. Samples were loaded on
Table 1 All 5′ primers contain a SacI and all 3′ primers a BglII site for cloning into pGl3-P vector
Name BRE 5′ primer (5′-3′) 3′ primer (5′-3′) size (bp)
7–13 GATGAGCTCATGCGAAAGTGAAGGTGGTCCCCAG TGAAGATCTAGCAAGGAGGAACTGGAGATGTCA 1278
9–13 GAGCTCTCGAACCTCTCTTTCCTATCTC AGATCTAGCAAGGAGGAACTGGAGATGTCA 695
10–13 GAGCTCTGGAGCTGAGCCTGGAGAGAAG AGATCTAGCAAGGAGGAACTGGAGATGTCA 530
12–13 GAGCTCTAGGCCATCAGACAGCTCTGAG AGATCTAGCAAGGAGGAACTGGAGATGTCA 127
9 GAGCTCTCGAACCTCTCTTTCCTATCTC AGATCTCTTCTCTCCAGGCTCAGCTCCA 189
9–10 GAGCTCTCGAACCTCTCTTTCCTATCTC AGATCTCCCTCATCTCTCCTTGCAGCT 253
9–11 GAGCTCTCGAACCTCTCTTTCCTATCTC AGATCTAGGCCCTCAAATTCCTCAGAG 348
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MACS separation columns (Miltenyi Biotec) and sub-
jected to magnetic immunoprecipitation. The columns
were washed 3 times with a wash buffer (150 mM NaCl,
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM
Tris-HCl, pH 8.0). Bound protein complexes were eluted
in 50 μl of pre-warmed SDS gel loading buffer 1X
(50 mM Tris-HCl, pH 6.8, 50 mM DTT, 1% SDS, 0.
005% bromophenol blue, 10% glycerol) and subjected to
Western Blotting for septin 7 as described above. A
mouse monoclonal anti-Paxillin antibody (1:2000; BD
Bioscience) was used as negative control.
MTT assay
To assess the putative toxic effects of Bt in MM cells,
the mitochondrial activity of living cells was determined
by the 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazo-
lium bromide (MTT) quantitative colorimetric assay.
MM cells (1500–3000 depending on the cell line) were
seeded in 96-well plates. From a stock solution (1 M
NaBt in PBS), different amounts were added to yield Bt
concentrations from 0.33 to 5 mM. After 3 days of incu-
bation with Bt, MM cells were subjected to the MTT
assay by adding fresh medium containing 0.5 mg/ml
MTT and incubating the plates for 90 min at 37 °C. The
supernatant was discarded and DMSO (200 μl) was
added to dissolve the formazan crystals. The absorbance
at 570 nm was measured using a microplate reader (In-
finite Pro200; Tecan Austria GmbH, Groedig, Austria).
For each experiment the absorbance value of untreated
(control) cells was defined as 1.0 (100%).
Statistical analysis
The data are presented as mean ± standard deviation of
multiple experiments (n ≥ 3). The statistics were per-
formed using StatPlus (AnalystSoft) applying a one-way
ANOVA followed by a post-hoc Tukey HSD test. Differ-
ences were considered as statistically significant if a p-
value was < 0.05.
Results
Butyrate induces CR expression in MM cells and also in
immortalized mesothelial cells
We analyzed the effect of Bt on CR expression levels in
cells derived from all MM histotypes. Bt concentrations
ranging from 0.5–2 mM applied for short periods (48
and 72 h) were tolerated to various degrees; higher Bt
concentrations (generally ≥2 mM) and prolonged expos-
ure (> 6 days) resulted in massive death of most of the
investigated MM cell lines (data not shown). Immortal-
ized mesothelial cells (Met-5A) and ZL34 cells derived
from a sarcomatoid MM showed massive cell death
already at 1–2 mM when treated for 6 days. In the few
surviving Met-5A cells CR expression levels were insig-
nificantly affected as reported before [15]. Here we
investigated the effect of Bt on CR expression levels at
72 h, a time point only mildly affecting cell viability. A
quantitative Bt concentration – cell proliferation/viabil-
ity curve was determined for MSTO-211H, ZL55 and
ZL5 cells, the lines used in most of the further experi-
ments (Additional file 1: Figure S1). The weakest effect
of Bt on the MTT signal intensity (cell proliferation/via-
bility) was observed in ZL5 cells, intermediate in
MSTO-211H cells and the strongest Bt-dependent effect
was seen in ZL55 cells. The shape of the curves is not
reminiscent of a typical sigmoidal toxicity curve, but ra-
ther for a growth-inhibiting effect of Bt, as had been ob-
served before in Bt-treated colon cancer cells and
immortalized LP9/TERT1 mesothelial cells (G1 arrest)
[3, 26]. In support, only few floating (dead) cells were
observed at the investigated concentrations and the se-
lected time point (72 h). Bt treatment of MSTO-211H
(biphasic) cells increased CR protein levels in a Bt
concentration-dependent way (Fig. 1a). An increase in
CR was also seen Met-5A cells, as well as in the epitheli-
oid MM cell lines ZL5 and ZL55, the biphasic cell line
SPC212 and the sarcomatoid cell line ZL34 (Fig. 1b).
Generally, cells derived from epithelioid and biphasic
MM are characterized by higher basal CR expression
levels than cells derived from sarcomatoid MM, in par-
ticular ZL34 and SPC111 cells, the latter with very low
basal CR expression levels [3, 14]. Bt treatment of all cell
lines led to a concentration-dependent increase in CR
levels; semi-quantitative evaluation of the CR signals of
the cell lines shown in Fig. 1b are depicted in Fig. 1c. Of
note, CR expression levels were determined in cells that
remained attached to the cell culture dishes, i.e. viable
cells and not the floating and/or dead cells in the culture
medium. Since MM cell lines of the epithelioid and bi-
phasic type were previously shown to be strongly af-
fected by CR down-regulation, much more than MM
cells derived from sarcomatoid tumors [3], further ex-
periments were carried out with ZL5 and ZL55 (epitheli-
oid) and MSTO-211H (biphasic) cells.
A region in the CALB2 gene promoter containing 7
putative BRE elements acts as a butyrate-responsive
enhancer in MSTO-211H and ZL55 MM cells
Analysis of the human CALB2 promoter region re-
vealed additional putative BRE elements named BRE7–
13 (Fig. 2b) upstream of the previously identified region
that contains 2 functional BRE (BRE5–6), which act as
transcriptional repressors in colon cancer cells [15].
The newly identified region has a length of 1278 bp
and is approximately 3.3 kb upstream of the CALB2
translation start site (ATG) (Fig. 2a). This 1.3 kb region
was amplified by PCR using genomic DNA from ZL55
and Met-5A cells and primers containing specific re-
striction sites (forward primer: SacI site; reverse primer
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BglII site) compatible with the reporter luciferase plas-
mid pGl3-P. Sequencing revealed the inserts amplified
from the 2 cell lines to contain alterations in the nu-
cleotide sequence when compared to the sequence an-
notated in PubMed (CALB2; gene ID: 794). The three
changes (1 point mutation (A/T), 2 deletions of either 1
or 2 nucleotides) were present in the sequences of all
clones derived from both cell lines, ZL55 and Met-5A,
excluding this being PCR artifacts (Additional file 1:
Figure S2). The others were specific for each cell line,
consisting of point mutations, 2 in the insert derived
from ZL55 cells and 3 in the insert derived from Met-
5A cells (Additional file 1: Figure S2). None of these
changes directly involved the sequences of the putative
BREs. Besides the luc + reporter plasmid containing all
7 putative BREs (BRE7–13), truncated versions were
generated by PCR and these included plasmids contain-
ing BRE9–13, 10–13 12–13, 9, 9–10 and 9–11 (Fig. 2c).
In MSTO-211H cells, luciferase activity was increased
by 41 ± 16% (mean ± SEM) by the full-length fragment
after Bt treatment for 48 h; however, strongest activa-
tion (200 ± 24% of control) was observed with the frag-
ment containing BRE9–13, while elimination of BRE9
(fragment BRE10–13), resulted in a luciferase activity
close to basal levels (109 ± 9%). In a shorter promoter
fragment that included BRE9 (BRE9–11), activity was
partially increased (159 ± 14%), but not to values as
seen with the BRE9–13 plasmid. Thus, the essential
enhancer/activator part appeared to be contained in the
region embracing BRE9–11, but the region containing
BRE12 and 13 further enhanced the luciferase activity,
indicative that the various BREs contributed to the ef-
fects in a rather complex manner. Similar results were
obtained in ZL55 cells, although the maximal effect in
the presence of the BRE9–13 promoter fragment was of
smaller magnitude (123 ± 18%). Thus, the effects were
nearly identical qualitatively (Fig. 2c, d), yet the effect
was approximately 4-times smaller in ZL55 cells. It is
noteworthy that the effect on the luciferase activity was
rather well correlated with the fold increase in CR ex-
pression levels after Bt treatment (Fig. 1). The increase
in CR expression was + 290% in MSTO-211H cells and
+ 60% in ZL55 cells, i.e. an approximately 5-fold differ-
ence. It appears that in ZL55 cells, where CR levels are
rather high in control conditions, the relative Bt-
mediated increase in CR expression is smaller than in
MSTO-211H cells characterized by a lower “basal” CR
expression level [14]. We also tested the BRE7–13 and
BRE9–13 promoter fragments containing the luc + re-
porter in the colon cancer cell line Caco-2 in order to
see, whether the enhancer function also persisted in
colonocytes. A small, yet insignificant increase of + 19
± 16% was observed in the presence of the BRE9–13
fragment and similar results were also observed with
HT-29 colon cancer cells (data not shown). This hints
that the BRE9–13-containing promoter region in the
CALB2 gene acts as a Bt-activated enhancer, with a
strong preference for MM cells.
Identification of proteins binding to CALB2 promoter
fragments BRE5–6 and BRE9–13 in a Bt-dependent
manner
In a previous study we had demonstrated that both
BRE5&6 contribute to the CR-repressing effect in colon
cancer cells [15]. Based on the rather complex pattern of
BRE-containing fragments on enhancing luciferase activ-
ity (Fig. 2c) involving up to 5 BREs [9–13], we addressed
the question, which proteins might bind to the BRE9–
13-embracing region in a Bt-dependent manner. For
this, cell lysates from Bt-treated and control MSTO-
211H cells were incubated with the biotinylated BRE9–
13 DNA fragment. Several proteins bound to the DNA
and were released in the presence of elution buffer (Fig. 3).
A side-by-side comparison of silver-stained polyacrylamide
Fig. 1 Upregulation of CR in Bt-exposed immortalized mesothelial
(Met-5A) and MM cells a Upper panel: CR Western blot of cytosolic
proteins from MSTO-211H cells treated with Bt for 72 h; left lane
(CR): human recombinant CR (40 ng) as control. Lower panel: Ponceau
Red-stained membrane to check for even loading. Ticks on the left mark
the position of marker proteins (in kDa, from top to bottom: 75, 35, 28,
10). The signal for CR is slightly above the 28-kDa marker protein. b
Western blots for CR of Bt-treated (72 h) cells: one mesothelial cell line
(Met-5A) and 4 MM cell lines: ZL55, ZL5, SPC212, ZL34. Equal loading
was confirmed by Ponceau Red staining as shown in a (not
shown). c Semi-quantitative CR Western blot results (Mean ± S.D.)
from 5 independent representative experiments. *** p < 0.001
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gels revealed few proteins bands differentially bound to the
BRE9–13 DNA fragment in the 2 conditions (± 1 mM Bt
for 72 h). In the Mr range of 35–50 kDa several strongly
stained bands were excised, digested by trypsin and ana-
lyzed by peptide shotgun mass spectroscopy (MS). Highly
expressed proteins binding to the CALB2 promoter region
included proteins implicated in transcription/translation
such as eukaryotic initiation factors 4A-I and –III (IF4A1,
EIF4A3) and elongation factors 1-alpha (EF1A1) and 1-
delta (EF1D) (Fig. 3a, b). Differentially expressed proteins
(± Bt) consisted of annexin A1 (ANXA1; gene ID: 301; Mr
38.7 kDa; − 19%). Even lower amounts of septin 7 (SEPT7;
gene ID: 989; Mr 50.7 kDa; − 34%), a member of the family
of GTP-binding proteins and serpin H1 (SERPH; − 54%),
also known as heat shock protein 47 (HSP47), reported to
function as a chaperone for collagen [27], were present in
the extracts of Bt-treated cells. Other proteins including
annexin A2 (ANXA2; gene ID: 302; Mr 38.6 kDa) and plas-
minogen activator inhibitor 2 (SERPINB2; gene ID: 5055;
Mr 47 kDa) were not differentially bound (Fig. 3b). Of inter-
est, the mesenchymal marker vimentin was also present in
the complex bound to BRE9–13 DNA and binding was in-
creased in the Bt-treated MSTO-211H samples (+ 44%).
Since the decrease in BRE9–13 DNA-bound proteins in-
cluding annexin A1 and septin 7 could be the result of a de-
creased binding or of a Bt-induced decrease in protein
expression, levels of annexin A1 and septin 7 were deter-
mined by Western blot analysis of either cytosolic proteins
or proteins eluted from the BRE9–13 DNA fragment in
control and Bt-treated MSTO-211H cells. Expression levels
of annexin A1 were increased in Bt-treated cells, while the
amount of annexin A1 bound to BRE9–13 DNA was nearly
unaffected by Bt. On the other hand, cytosolic septin 7
levels were slightly decreased by the Bt treatment in these
conditions, while the amount of septin 7 bound to BRE9–
13 DNA was clearly lower after Bt treatment (Fig. 3c). To
further demonstrate the specificity of the effect, similar ex-
periments were carried out with the previously described
DNA fragment containing BRE5–6, shown to act as a Bt-
responsive repressor element in colon cancer cells [15]. In
parallel, we compared binding of annexin A1 to both BRE-
containing fragments, BRE5–6 and BRE9–13 using cyto-
solic extracts from control or Bt-treated MSTO-211H cells
(Fig. 3d). Elution of bound proteins was carried out in 2
conditions: weakly bound proteins eluted in fraction E1 and
strongly bound proteins in fraction E2. Since no striking
Fig. 2 Sequence of the human CALB2 promoter region containing putative Bt-responsive elements BRE7–13 a The region of 1278 bp contains 7
putative BREs (cyan). Primer sequences to amplify the 1278-bp fragment are marked in yellow including restriction sites for SacI (Table 1) and BglII
(red). The start site of translation is marked in red (bold). Primers used to amplify truncated versions are boxed in gray (details are shown in Table 1). b
Sequence alignment of BRE5 - BRE13 with the BRE consensus sequence (15) shown at the bottom. Nucleotide sequences fully complying with the
consensus (100% identity) are marked in blue, medium-conserved sequences are marked in green and nucleotides not conferring to the consensus
sequence are marked in black; percentages of identity with the consensus sequence are given in the right lane. c, d Luc + reporter assay in MSTO-
211H (upper) and ZL55 MM (lower) cells with CALB2 promoter fragments containing variable numbers of BREs. Luc + activities were normalized to the
signal obtained with the control plasmid pGl3-P. As reference for the statistical analysis, BRE5–6 [15] was used. The number of independent experi-
ments ranged from n = 4 (e.g. BRE10–13) to n = 11 (e.g. BRE7–13). Values represent mean ± S.D. *p < 0.05 vs. BRE5–6
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qualitative differences were observed with respect to pro-
teins eluted in fractions E1 and E2, the results from elution
conditions E1 and E2 were combined. Similar as shown in
Fig. 3c, the signal for septin 7 eluted from immobilized
fragment BRE9–13 was clearly weaker using extracts from
Bt-treated cells. Yet no significant differences were ob-
served when using DNA fragment BRE5–6 as bait. An
inverse situation was observed for annexin A1: increased
binding to fragment BRE5–6 using extracts of Bt-treated
cells and no striking changes in the binding to fragment
BRE9–13 (Fig. 3d). In summary, annexin A1 preferentially
bound to the DNA fragment BRE5–6 in a Bt-dependent
manner, while septin 7 showed a Bt-sensitive decrease in
binding to BRE9–13. Since BRE9–13 acted as a Bt-sensitive
activator of CALB2 promoter activity and septin 7 bound
to BRE9–13 was found to be decreased in extracts from Bt-
treated cells, we reasoned that septin 7 might be a negative
transcriptional regulator of CR expression by its binding
within a protein complex that binds to the CALB2 pro-
moter in MSTO-211H cells.
Calretinin and septin 7 act as negative transcriptional
regulators of each other in MM cells and are inversely
regulated by Bt
First, we investigated CR and septin 7 expression levels
in immortalized human mesothelial cells and in human
MM cell lines (Fig. 4a). Plotting CR vs. septin 7 levels of
all tested cell lines revealed a clear clustering: epithelioid
MM (ZL55, ZL5, JL1 and H226) and biphasic MM cells
with a major part of epithelioid cells (MSTO-211H)
formed the group of high CR-expressing cells (Fig. 4b).
Somewhat lower CR levels were found in immortalized
mesothelial cells (MeT-5A and LP9/TERT1), followed by
the biphasic MM lines with mostly sarcomatoid cells
(SPC111, SPC212 and H28) and sarcomatoid cells
(ZL34). A clear inverse correlation was also detected in
Bt-treated MM cells, where CR and septin 7 levels were
determined after 72 h of Bt (1 & 2 mM) treatment. In
MeT-5A, ZL55, ZL5, SPC212, ZL34 and MSTO-211H
cells CR levels increased (as also shown in Fig. 1), while
at the same time septin 7 was clearly down-regulated;
representative examples of ZL5 and MSTO-211H cells
are shown in Fig. 4c1 and c2. Since these results merely
indicated inverse regulation between CR and septin 7
expression by Bt in all investigated MM lines, the next
experiments were aimed to alter either CR or septin 7
expression levels to determine the effect on the expres-
sion levels of the other protein.
Thus, to directly investigate whether septin 7 acts as a
negative transcriptional regulator of CR expression, sep-
tin 7 levels were increased by lentiviral infection of
MSTO-211H cells with LV-SEPT7. The increase in
Fig. 3 Proteins differentially bound to the BRE9–13 DNA fragment a Silver-stained gel of proteins eluted from the BRE9–13 DNA-containing
column from control MSTO-211H cells (−) or from Bt-treated (1 mM) cells (+) for 72 h; the region between 35 and 50 kDa (black bar) showed
the strongest signals. A band was clearly weaker in extracts from Bt-treated cells (arrow). b Differentially expressed proteins listed (from top to
bottom) according to their abundance in the samples analyzed by peptide shotgun MS. c Western blot for annexin A1 (top) and septin 7 (bottom) of
either total cytosolic proteins (left) or of the proteins bound to the BRE9–13 DNA (right). d Binding assay of MSTO-211H soluble whole cell extracts with
either a DNA fragment containing BRE5–6 or BRE9–13 identified as the septin 7-binding region of the CALB2 promoter. Eluate E1 was obtained after
low stringency conditions, E2 under high stringency conditions
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Fig. 4 Analysis of septin 7 and CR levels in different cell lines of mesothelial origin and after experimental manipulations. a Relative expression
levels of CR and septin 7 in various cell lines of mesothelial origin. b Semi-quantification of CR and septin 7: brown dots represent immortalized
mesothelial cells, red dots epithelioid MM, orange dots bi-phasic and yellow dots sarcomatoid MM cell lines. c Effect of Bt administration on CR
and septin 7 levels in MSTO-211H (C1) and ZL5 cells (C2). d Extracts of MSTO-211H cells infected with LV-septin7 or LV-GFP; note the decrease in
CR in cells overexpressing septin 7. e MSTO-211H cells treated with Bt (+) or not (−) and subjected to down-regulation of septin 7 by shSEPT7;
shGFP served as a negative control. f Up-regulation of CR by LV-CALB2 in SPC212 and HT-29 cells; note the decrease in septin 7 levels. The
complete Ponceau-stained membranes corresponding to the Western blots shown in a and d are shown in Additional file 1: Figure S3
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septin 7 levels led to a down-regulation of CR expression
(Fig. 4d), consistent with the previous results that lower
amounts of septin 7 bound to BRE9–13 after Bt treatment
are correlated with increased CR expression (Fig. 3c). As a
negative control, a lentivirus expressing GFP had no effect
on CR expression levels. The opposite, i.e. down-
regulation of septin 7 by SEPT7 shRNA strongly inhibited
cell proliferation, decreased viability and many dying non-
adherent cells were observed; the surviving cells had
mostly a spindle-shaped morphology typical for the low
CR-expressing subpopulation with sarcomatoid morph-
ology of MSTO-211H cells (not shown). While the Bt-
induced increase in CR was also seen in shSEPT7-treated
cells, septin 7 down-regulation did not noticeably affect
CR levels in the surviving MSTO-211H cell population
when compared to levels in cells infected with GFP
shRNA (Fig. 4e). Since the Bt-induced increase in CR was
associated with a decrease in septin 7 as evidenced in con-
trol and GFP shRNA treated MSTO-211H cells (Fig. 4e)
indicative of a negative feedback regulation, we investi-
gated the direct effects of CR overexpression on septin 7
levels. Lentivirus-mediated upregulation of CR using
previously developed tools [25] caused a clear decrease in
septin 7, irrespective, whether MSTO-211H cells were
treated with Bt or not (Fig. 4e). This indicates that CR is a
Bt-independent, negative regulator of septin 7. The inverse
experiment with shCALB2 was not conclusive, since
shCALB2-mediated down-regulation of CR resulted in
massive cell death as reported before [3], thus not allow-
ing to investigating septin 7 levels.
The effect of CR overexpression on septin 7 levels was
investigated in SPC212 cells, as well as in the CR-
expressing colon carcinoma cell line HT-29, previously
shown to negatively modulate CR expression in a Bt-
dependent way [15]. In both cell lines, CR overexpres-
sion led to a clear decrease in septin 7 levels (Fig. 4f ).
This supports the hypothesis that CR functions as a
negative regulator for septin 7 in two different cell types
(mesothelial cells, colonocytes). In summary, treatment
with Bt increases CR levels in all histotypes of MM cells
and decreases septin 7 levels (data shown for MSTO-
211H and ZL5 cells). Finally, overexpression of either
one decreases expression levels of the other. These
results are indicative of a finely tuned balance between
expression levels of the 2 proteins.
Calretinin and septin 7 are co-expressed during mouse
embryonic development and septin 7 levels are higher in
primary mesothelial cells from mice without a functional
Calb2 gene
Based on previous findings that CR is expressed in spe-
cific regions within the mesenchyme of murine embryos
and in precursor mesothelial cells in the developing lung
at embryonic days 14.5 and 16.5 [25], we investigated
the expression of CR and septin 7 on serial sections de-
rived from mouse embryos at E10.5. Expression patterns
for CR and septin 7 showed an almost complete overlap
in the mesenchyme of E10.5 mice (Fig. 5a, b); yet the in-
tensity of staining for one or the other protein varied no-
ticeably. Since transient CR expression is observed in
the mesenchyme and developing mesothelial cells [25],
we wondered whether CR’s absence during this period in
CR−/− mice would affect the expression of septin 7 in
the terminally differentiated mesothelium. For this, pri-
mary mesothelial cells (prMC) were isolated from either
WT or CR−/− mice and kept in cell culture in vitro for
10–15 days. Western blots revealed clearly higher levels
of septin 7 in mesothelial cells from CR−/− mice com-
pared to WT animals (Fig. 5c). Thus, the transient ex-
pression of CR in developing mesothelial cells had a
long-lasting effect on septin 7 expression; it appeared
that CR acted as a long-lasting repressor of septin 7
synthesis. A similar analysis was carried out in primary
mesothelial cells immortalized with SV40. The expres-
sion of SV40 Tag/tag was previously shown to substan-
tially increase the proliferation rate of primary
mesothelial cells, both from WT and CR−/− mice [25].
Interestingly, in SV40-immortalized cells, septin 7 ex-
pression levels were strongly increased independent of
the genotype (WT vs. CR−/−; Fig. 5c, right panel).
Binding of septin 7 to calretinin and co-localization of the
two proteins in distinct regions of the cleavage furrow
and in the midbody region during cytokinesis
Based on the co-expression of CR and septin 7 in cells
from embryonic mesenchymal tissue, we investigated in
more detail, the intracellular localization of the two pro-
teins in human MM cells. Since CR immunostaining
was rather weak in most untreated MM cell lines, im-
munofluorescence staining against CR was mostly
carried out in cells overexpressing CR or in Bt-treated
cells characterized by elevated CR expression levels.
Qualitatively, CR intracellular localization was similar in
all three conditions: control, CR-overexpressing, Bt-
treated cells (data not shown). Septin 7 was either con-
fined to the cell cortex, a zone implicated in the dynamic
interplay between plasma membrane proteins and the
cytoskeleton and to filamentous structures, likely the so-
called “septin cytoskeleton” consisting of septin hetero-
polymers (Fig. 6a1). In the same cell (e.g. Bt-treated
MSTO-211H), the intracellular distribution of CR was
rather homogenous (Fig. 6a2), yet with a stronger stain-
ing of perinuclear intermediate filaments and sometimes
microtubules as reported before in WiDr colon cancer
cells [28]. In WiDr cells a direct association of CR with
these cytoskeletal structures has been reported previously,
also based on co-immunoprecipitation experiments. The
merged images including DAPI staining (Fig. 6a4) showed
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some colocalization (yellow color) that was further investi-
gated in the different MM cell lines. During telophase sep-
tin 7 was strongly localized to the zone of the cleavage
furrow (Fig. 6b1). Also CR staining was stronger in the re-
gion of cell cleavage sometimes resulting in a yellow zone
indicating that the proteins were concentrated in this re-
gion (Fig. 6b2). During the early phase of cytokinesis the
center of the midbody showed strong “septin 7 only”
staining (red) (Fig. 6b3–6), followed first by a yellow zone
(septin 7 and CR) and finally by a green one (CR only). In
some rare cases the center of the midbody was stained for
CR only (Fig. 6b8). Based on the co-localization of these
proteins in some regions, we determined whether these
two proteins directly interact. Co-immunoprecipitation
revealed that in the lysate from MSTO-211H-CR and
ZL55-CR cells incubated with anti-CR antibody, septin 7
was pulled down (Fig. 6c). These results suggested that
CR and septin 7 have the predisposition to interact dir-
ectly, but that other putative binding partners of either CR
or septin 7 or different conformations of either protein
prevented this interaction to take place throughout the
cell. Their close spatial apposition (at times even co-
localization indicative of direct interaction) and the pre-
cise time points during cytokinesis indicates that the 2
proteins are likely implicated in the same biological
process, namely in cytokinesis, yet have on occasion dis-
tinct localizations and thus probably non-identical, but
conceivably complementary functions (see discussion).
Discussion
Although CR is currently used as a positive marker for
the unequivocal identification of human MM of the epi-
thelioid and mixed type [1, 2], still little is known I)
about whether CR is implicated in the etiology of MM,
II) on the regulation of CR in cells of mesothelial origin
and III) about the function(s) of CR in MM cells. Details
on the regulation [14] and possible function [3] of CR in
MM are only slowly emerging. We had previously
reported that Bt acts as repressor of CR expression in
CR-positive colon cancer cells via BREs present in the
CALB2 promoter [15]. The same elements BRE5–6 were
found to be essentially non-functional in the immortal-
ized mesothelial cell line Met-5A.
We had hypothesized that injury of the intestinal wall
or damage of the lung tissue by e.g. asbestos fibers might
lead to the colonization of the tunica serosa of the peri-
toneal or pleural cavity by facultative anaerobic bacteria
(e.g. Streptococcus pneumoniae, Staphylococcus aureus,
Chlamydia pneumoniae in airways or gut microbiota)
producing Bt resulting in concentrations in the millimolar
Fig. 5 Co-expression of calretinin and septin 7 Immunohistochemical analysis of E10.5 lung tissue stained for CR a1 and a2 and septin 7 b1 and
b2. Scale bars: 250 μm for a1 and b1, and 50 μm for a2 and b2. c Left: Septin 7 Western blot of extracts from cultured primary mesothelial cells
from C57Bl/6J (WT) and CR−/− mice; note the lower levels of septin 7 in WT cells. Right: Septin 7 Western blot from SV40-immortalzed
mesothelial cells derived from WT and CR−/− mice. As loading control (l.c.) an endogenous biotinylated protein (Mr ≈ 75 kDa) was used.
The complete Ponceau Red-stained membrane is shown in Additional file 1: Figure S3
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range [19]. Thus, we tested the effect of Bt on CR expres-
sion levels in immortalized mesothelial cells and several
human MM cell lines of all histotypes, the former serving
as a model for “reactive” mesothelial cells. The observed
strong, rapid and Bt-concentration dependent increase in
CR expression depended on the presence of a positive
regulatory element in the CALB2 promoter containing
additional BREs. Unexpectedly, septin 7, generally consid-
ered as a structural protein was found to be part of this
regulatory transcriptional complex. Septin 7 belongs to a
family of RAS-like GTP-binding and membrane-interacting
proteins; currently 13 septin genes subdivided into four dis-
tinct groups are known in mammals and septin family
members are characterized by a highly conserved domain
structure [29]. The different septins are involved in various
cellular processes mostly implicated in cell morphology dy-
namics including cytoskeleton organization, cytokinesis and
membrane dynamics (e.g. curvature), for a review see [29].
Besides septins’ well-characterized preference for protein-
protein interactions among own family members, forming
higher-order structures such as filaments, bundles, scaffold-
ing structures or rings, many other septin-interacting pro-
teins have been identified forming the septin interactome
(see Table 1 in [30]). In many cases these proteins are asso-
ciated with the actin and/or microtubule cytoskeleton or
with phospholipid membranes. Interestingly, the cdk1-
dependent phosphorylation of septin 9 regulates the associ-
ation with the proline isomerase (Pin1) implicated in the
disjunction of daughter cells. The observed strong staining
of septin 7 at the site of daughter cell separation indicates
that septin 7 might have a similar function in MM cell
cytokinesis. In support, septin 7-deficient fibroblasts show
defects in the machinery implicated in cytokinesis including
stabilization of microtubules and stalled midbody abscission
Fig. 6 Intracellular localization of calretinin and septin 7 in MM cells a Septin 7 localization (red; a1) and CR (green; a2) in MSTO-211H cells
treated with 1 mM Bt. Cortical regions (arrows) and cytoskeletal-like structures (filaments, bundles; arrowheads) are strongly stained for septin 7.
a3 Nuclear DAPI staining. a4) Merged images a1–3). Scale bars: 10 μm. b Localization of septin 7 (red) and CR (green) at different stages of
cytokinesis starting from early telophase b1 until close to cell separation b8] in MM cell lines. Yellow indicates colocalization of the 2 proteins.
DAPI-stained nuclei are shown in blue. Scale bars in all images: 10 μm. 1) MSTO-211H-CR; 2) MSTO-211H treated with 1 mM Bt; 3) MSTO-211H-CR;
4) MSTO-211H treated with 1 mM Bt; 5) MSTO-211H-CR; 6) SPC111-CR; 7) ZL55-CR; 8) SPC212-CR. c Co-IP with lysates from MSTO-211H-CR and
ZL55-CR cells. Proteins binding to CR were co-immunoprecipitated with a CR antibody. Membranes with PAGE-separated proteins were probed
for CR and septin 7 (lane IP). Input samples containing all proteins (prior to immunoprecipitation) were probed for the same proteins. Paxillin was
used as negative control
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[31]. The latter defect was shown to also lead to
multinucleation.
Knowledge on the role of septins in gene regulation is
sparse. Septin 9 is capable of interacting with the
hypoxia-inducible factor 1 alpha HIF-1α acting as a posi-
tive regulator in the hypoxic pathway leading to in-
creased proliferation, soft agar clonal survival and tumor
growth [32]. In our study we observed that binding of
septin 7 to the transcriptional complex driving CALB2
expression was decreased after Bt treatment. Since the
Bt-dependent decrease in septin 7 binding to the protein
complex bound to CALB2 BRE7–13 leading to increased
CR levels might be the result of different processes, we
selectively manipulated septin 7 expression in MM cell
lines. Of note, Bt treatment had no effect on septin 7 ex-
pression levels and moreover down-regulation of septin
7 levels by shSEPT7 had no effect on CR expression. On
the other hand overexpression of septin 7 led to a strong
decrease in CR expression levels indicating that septin 7
acts as a negative regulator (repressor) of CR expression.
The mechanism was operating bi-directionally, i.e. CR
overexpression resulted in a decrease in septin 7 levels.
In line, a comparison of primary mesothelial cells (prMC)
from WT and CR−/− mice revealed higher septin 7 levels
in CR−/− prMC, albeit the fact that in these cells isolated
from young adult mice, CR expression levels are below
the detection limit of Western blot analysis [25].
In summary, these results indicate that both, CR and
septin 7 act as negative transcriptional regulators for
each other. As CR expression levels in tumor specimen
are used to diagnose the clinical outcome, i.e. lower CR
levels are a poor prognostic factor [33], also deregulated
septin expression has been linked to tumor develop-
ment/growth [34]. Increased levels of septin 2, 8, 9, 11
and decreased levels of septin 4 and 10 have been con-
sistently reported in various tumor types and are as-
sumed to act as oncogenes and tumor suppressor genes,
respectively [34]. Evidently in order to exert an antagon-
istic regulatory function, CR and septin 7 need to be co-
expressed in situ, i.e. within the same cells. This was
clearly evident during normal mouse embryonic develop-
ment, where the two proteins colocalize in mesenchymal
cells during lung development. While our experiments are
in clear support of an inverse regulation, the colocalization
and/or close apposition of each other might hint towards
an implication in the same process, i.e. in cytokinesis.
Immuno-EM images of WiDr colon cancer cells stained
with an anti-CR antiserum had previously revealed CR
staining during early telophase at the midbody, while at
later stages the midbody zone was completely negative
(see Fig. 2f-i in [35]). Essentially identical findings on CR
localization during cytokinesis were observed in various
MM cell lines. Also septin 7 staining was particularly
strong first at the cleavage furrow and then in distinct
parts of the midbody. Of note, strong co-localization was
not observed during the entire separation of the daughter
cells; at distinct time points and precise midbody
localization one or the other protein was more prevalent
resulting in a clear separation of the green and red fluores-
cence. Yet occasionally, the strong yellow color indicated
the 2 proteins to be colocalized at the same regions and
co-IP experiments confirmed a direct interaction between
CR and septin 7.
Septins have been also shown to associate to the
mitotic spindle, being required for cytokinesis [31];
the same had been reported for CR-expressing WiDr
cells [35, 36].
Conclusions
In this report we have identified septin 7, an essential
cellular component implicated in the final steps of cell
division, as a strong Bt-dependent gene regulatory pro-
tein binding to the promoter of CALB2. Moreover,
septin 7 was negatively regulated by CR forming a feed-
back loop. Our study adds knowledge on the molecular
mechanism involved in up-regulation of CR caused by
Bt, a step that might also be implicated in mesothelio-
magenesis. Since CR has been proposed to serve as a pu-
tative target for MM therapy due to its essential role in
MM cell lines [3], indirectly targeting CR through septin
7 and/or directly targeting septin 7 might represent yet
another strategy for the development of a therapy to
treat the currently incurable MM.
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Additional file 1: Figure S1. MTT assay of different MM cell lines
exposed to butyrate (Bt). Relative MTT signals for A) MSTO-211H, B) ZL55
and C) ZL5 MM cells exposed to various Bt concentrations ranging from
0.33 to 5 mM. Results are from 3 independent experiments (each sample
in triplicate). The value of untreated cells in each experiment was defined
as 100%. Results represent mean±SEM. Figure S2. Point mutations in the
PubMed database sequence (CALB2; gene ID: 794) of the CALB2 promoter
region containing BRE7-13 in comparison to human Met-5A and ZL55
cells are boxed in green (Met-5A) or yellow (ZL55). Insertions or deletions
found in the sequence of all analyzed cell lines are boxed in cyan. None
of the mutations concern the 7 BRE listed in Fig. 2. Figure S3. Top panel:
Ponceau-Red stained membrane used for the Western blot shown in Fig. 4a.
Sizes of marker proteins range from 17 kDa (faintly stained lowest band mark-
ing gel front) to 100 kDa (most upper band). Middle panel: Ponceau-Red
stained membrane used for the Western blot shown in Fig. 4d. The size of
marker proteins ranges from 20 kDa to 135 kDa. Lower panel: Ponceau-Red
stained membrane used for the Western blot shown in Fig. 5c. The size of
marker proteins ranges from 20 kDa to 135 kDa. (DOCX 1083 kb)
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